Local Bounti Earnings Call Transcripts
Fiscal Year 2026
-
Revenue rose 14% year-over-year to $13.9 million, with improved adjusted EBITDA loss and expanded retail partnerships. Operational upgrades boosted yields, while new investments strengthened the balance sheet. Food safety trends and retailer demand for traceability are driving long-term growth.
-
The meeting covered director elections, auditor ratification, share issuance approval, and procedural matters. All proposals passed with a quorum present, and no stockholder questions were submitted during the Q&A.
-
Q1 2026 saw 15% revenue growth, improved margins, and a reduced net loss, driven by operational efficiency and commercial momentum. Strategic investments and new retail partnerships support a positive outlook toward profitability.
Fiscal Year 2025
-
Q4 2025 saw 24% revenue growth, improved margins, and reduced losses, with all facilities at full capacity and strong commercial momentum. Strategic investments and debt restructuring enhanced financial flexibility, positioning for continued progress toward profitability in 2026.
-
Q3 2025 saw 19% revenue growth, improved margins, and major operational gains, with Texas at full capacity and cost reductions underway. Strategic partnerships and new product launches are driving commercial momentum, with positive adjusted EBITDA targeted for early 2026.
-
Q2 2025 saw 28% revenue growth to $12.1M, improved margins, and a reduced adjusted EBITDA loss, driven by operational efficiencies and new facility output. Cost savings and capital restructuring strengthened the balance sheet, with positive adjusted EBITDA targeted for early 2026.
-
Q1 2025 revenue grew 38% year-over-year to $11.6M, with improved margins and a 20% yield boost in Georgia. Positive adjusted EBITDA is targeted for Q3, supported by cost reductions, new products, and expanded retail partnerships.
Fiscal Year 2024
-
Leadership transition and major debt restructuring position the company for growth, with sales up 38% year-over-year and positive adjusted EBITDA targeted for Q3 2025. Expanded distribution and operational improvements support a strong outlook.
-
Q3 2024 sales rose 50% year-over-year to $10.2 million, driven by new facilities and specialty products, though revenue fell short due to a strategic product mix shift. Adjusted gross margin improved to 32%, and positive Adjusted EBITDA is now targeted for Q2 2025.
-
Sales rose 31% year-over-year to $9.4M, with improved margins and reduced SG&A. New facilities in Texas and Washington ramped quickly, supporting expanded distribution and new SKUs. Full-year sales guidance of $50–$60M reiterated, with positive Adjusted EBITDA targeted for early 2025.